Nathan P. Wiederhold, Pharm.D.

• Professional Background

  Education

  • 2004 - Postdoctoral Fellowship - Medical Mycology Research Fellowship - University of Houston & University of Texas MD Anderson Cancer Center
  • 2002 - Residency - ASHP Accredited Infectious Diseases Residency - Barnes Jewish Hospital
  • 2001 - Residency - ASHP Accredited Pharmacy Practice Residency - Barnes Jewish Hospital
  • 2000 - PharmD - Pharmacy (Cum Laude) - University of Texas at Austin
  • 1996 - BA - Biology - University of Texas at Austin

  Appointments

  • 9/2018 - Professor with Tenure - The University of Texas Health Science Center at San Antonio, Pathology, San Antonio
  • 1/2013 - Director - Fungus Testing Laboratory, Department of Pathology, The University of Texas Health Science Center at San Antonio, Pathology, San Antonio
  • 1/2013 - Adjoint Associate Professor - The University of Texas at Austin, College of PharmacyAustin

• Instruction & Training

  • 9/2013 - Present, Attack and Defense, The University of Texas Health Science Center
  • 3/2013 - Present, Clinical Pathology, The University of Texas Health Science Center
  • 1/2011 - Present, PHR 675E, Pharmacotherapy II
  • 1/2008 - Present, MICR 5025, Core Concepts in Microbiology and Immunology
  • 9/2007 - Present, PHR 381W, Molecular and Pharmacological Basis of Therapeutics
  • 9/2004 - Present, PHR 384D, Antimicrobials: Their Mechanisms of Action and Clinical Use

• Research & Grants

  Grants

  Federal

  Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - In Vitro Screening for Antifungal Activity (NIH/NIAID 75N9301D00022 - Task Order A04) Status Active Period 5/2019 - 5/2020 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to test investigational compounds for in vitro activity against different pathogenic fungi. In addition, compounds may be screened for in vitro activity against Pneumocystis. Funding Agency NIH/NIAID Title Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates Status Active Period 2/2019 - 1/2020 Role Co-Investigator Grant Detail The purpose of this study is to evaluate the in vitro and in vivo activity of libraries of known compounds for antifungal activity to determine if they may be repurposed for the treatment of invasive fungal infections. Funding Agency NIH/NIAID Title Therapeutics Testing in Murine Models of Fungal Infections ? Coccidioidomycosis (NIH/NIAID ? HHSN272201000039I - Task Order A20) Status Active Period 8/2018 - 12/2019 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to determine the pharmacokinetics of investigational antifungal agents and evaluate their efficacy in murine models of pulmonary and CNS coccidioidomycosis. Funding Agency NIH/NIAID Title In Vitro Testing for Antimicrobial Resistant-Related Antimicrobial Activity (NIH/NIAID HHSN272201100018I Task Order A36) Status Complete Period 5/2018 - 4/2019 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to screen investigational compounds for activity against various bacteria, including multi-drug resistant clinical gram-positive and gram-negative strains. Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - In Vitro Screening for Antifungal Activity (NIH/NIAID HHSN272201100018I Task Order A33) Status Complete Period 4/2018 - 3/2019 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to test investigational compounds for in vitro activity against different pathogenic fungi. In addition, compounds may be screened for in vitro activity against Pneumocystis and for mammalian cell toxicity. Funding Agency NIH/NIAID Title In Vitro Testing for Antimicrobial Resistant-Related Antibacterial Activity - CARB-X (NIH/NIAID HHSN272201100018I Task Order A32) Status Complete Period 2/2018 - 1/2019 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to screen investigational compounds for activity against various bacteria, including multi-drug resistant clinical gram-positive and gram-negative strains. Funding Agency NIH/NIAID Title Therapeutics Testing in Murine Models of Fungal Infections ? Candida auris, Scedosporium sp.? (NIH/NIAID ? HHSN272201000039I - Task Order A01) Status Active Period 12/2017 - 9/2018 Role Co-Principal Investigator Grant Detail The purpose of this study is to assess the in vivo pharmacokinetics of an investigational antifungals agent and their efficacy in murine models of invasive candidiasis caused by Candida auris and invasive scedosporiosis. Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - In Vitro Screening for Antimicrobial Resistant-related Antibacterial Activity - CARB-X (NIH/NIAID HHSN272201100018I Task Order A29) Status Complete Period 5/2017 - 5/2018 Role Co-Investigator Grant Detail The purpose of this NIH/NIAID contract is to screen investigational compounds for activity against various bacteria, including multi-drug resistant clinical gram-positive and gram-negative strains. Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - In Vitro Screening for Antifungal Activity (NIH/NIAID HHSN272201100018I Task Order A28) Status Complete Period 3/2017 - 2/2018 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to test investigational compounds for in vitro activity against different pathogenic fungi. In addition, compounds may be screened for in vitro activity against Pneumocystis and for mammalian cell toxicity. Funding Agency NIH/NIAID Title Antifungal In vivo Efficacy Testing - Coccidioides (NIH/NIAID ? HHSN272201000038I - Task Order A98) Status Complete Period 8/2016 - 8/2017 Role Co-Principal Investigator Grant Detail The purpose of this NIH/NIAID contract is to determine the pharmacokinetics of investigational antifungal agents and evaluate their efficacy in murine models of pulmonary and CNS coccidioidomycosis. Funding Agency NIH/NIAID Title Therapeutics Testing in Murine Models of Aspergillosis and Candidiasis (NIH/NIAID ? HHSN272201000038I - Task Order A107) Status Complete Period 3/2017 - 8/2017 Role Co-Principal Investigator Grant Detail The purpose of this study is to assess the in vivo pharmacokinetics of an investigational antifungal agent and its efficacy in murine models of invasive aspergillosis and candidiasis. Funding Agency NIH/NIAID Title Gender Differences in Murine Models of Fungal Infections - Mucormycosis (NIH/NIAID ? HHSN272201000038I - Task Order A102) Status Complete Period 8/2016 - 8/2017 Role Co-Investigator Grant Detail This purpose of this NIH/NIAID contract is to assess for differences between males and females, both in terms of pathogenesis and response to antifungal therapy, in established murine models of pulmonary mucormycosis. Funding Agency NIH/NIAID Title Development of a New System for Scaled Up Culture and Propagation of Pneumocystis (NIH/NIAID HHSN272201100018I Task Order A22) Status Active Period 8/2016 - 7/2017 Role Co-Principal Investigator Grant Detail Funding Agency NIH/NIAID Title Gender Differences in Murine Models of Fungal Infections - Aspergillosis (NIH/NIAID ? HHSN272201000038I - Task Order A97) Status Active Period 7/2016 - 7/2017 Role Co-Principal Investigator Grant Detail This purpose of this NIH/NIAID contract is to assess for differences between males and females, both in terms of pathogenesis and response to antifungal therapy, in established murine models of invasive pulmonary aspergillosis. Funding Agency NIH/NIAID Title In Vitro Assessment for Antimicrobial Activity Part A Task Order Solicitation - In Vitro Screening for Antibacterial Activity (NIH/NIAID HHSN272201100018I Task Order A26) Status Complete Period 7/2016 - 7/2017 Role Co-Investigator Grant Detail The purpose of this NIH/NIAID contract is to screen investigational compounds for activity against various bacteria, including multi-drug resistant clinical gram-positive and gram-negative strains.

  Private

  Funding Agency Astellas Pharmaceuticals Title Susceptibility Patterns of the Investigational Agent Isavuconazole Against Clinical Isolates of Systemic Fungi and Other Fungi Status Complete Period 2/2013 - Present Role Co-Principal Investigator Grant Detail Funding Agency Astellas Pharmaceuticals Title Determination of the Species Identification of Clinical Isolates of Systemic Fungi and other Fungi Status Complete Period 2/2013 - Present Role Co-Principal Investigator Grant Detail Funding Agency bioMerieux Title Vitek MS MALDI-TOF to Determine Protein Profiles of Clinically-Significant Fungi Status Active Period 11/2012 - Present Role Co-Investigator Grant Detail Funding Agency Medicis Pharmaceuticals Title Antifungal Susceptibility Testing of Naftifine Against Clinically Significant Dermatophytes Status Complete Period 7/2013 - 6/2029 Role Co-Principal Investigator Grant Detail Funding Agency Merz Title Antifungal susceptibility testing against clinically significant dermatophytes (Merz 4024) Status Complete Period 7/2014 - 6/2029 Role Principal Investigator Grant Detail Funding Agency bioMerieux Title Vitek 2 and Vitek 2 Challenge, Reproducibility, and Clinical Evaluation Study Status Active Period 12/2017 - 12/2020 Role Principal Investigator Grant Detail Funding Agency Biolab Pharmaceutica Title In vitro evaluation of dapaconazole activity against fungi Status Active Period 11/2016 - 7/2020 Role Principal Investigator Grant Detail Evaluate the in vitro activity of dapaconazole and similar investigational compounds against different fungal species Funding Agency Astellas Pharma Global Title Isavuconazole Post-Marketing Surveillance & Registry Study - Invasive Aspergillosis & Mucormycosis Status Active Period 7/2015 - 6/2020 Role Principal Investigator Grant Detail The objective of this study is to perform antifungal susceptibility testing and species identification on all Aspergillus species and members of the Order Mucorales that are received by the Fungus Testing Laboratory for clinical testing. This post-marketing study was mandated by the FDA following approval of isavuconazole for clinical us in the United States. Funding Agency Cepheid Title Pre-Clinical study of the Xpert Xpress MVP Test Status Active Period 9/2018 - 5/2020 Role Principal Investigator Grant Detail Our role was to serve as the reference laboratory for the identification of all yeast isolates collected during the course of the study. Funding Agency Cidara Therapeutics, Inc. Title Rezafungin Treatment against Disseminated Aspergillosis caused by Azole-Resistant Aspergillus fumigatus. Status Complete Period 6/2018 - 6/2019 Role Principal Investigator Grant Detail Evaluate the in vivo activity of the investigational echinocandin rezafungin in an murine model of disseminated aspergillosis caused by an azole-resistant A. fumigatus isolate. Funding Agency Viamet Pharmaceuticals, Inc. Title In vitro Activity of the Fungal Specific Cyp51 Inhibitors against Azole Resistant Candida albicans and Non-albicans Candida Species Status Complete Period 3/2017 - 2/2019 Role Principal Investigator Grant Detail Funding Agency Cidara Therapeutics, Inc. Title Evaluation of CD101 In vitro Activity against Aspergillus Species Status Complete Period 8/2017 - 8/2018 Role Principal Investigator Grant Detail The in vitro potency of CD101 (now rezafungin) was evaluated against Aspergillus species, including azole-resistant A. fumigatus Funding Agency F2G, Limited Title In vitro activity of the Dihydroorotate Dehydrogenase Inhibitor F901318 Against Fusarium Species Status Active Period 2/2016 - 1/2018 Role Principal Investigator Grant Detail Funding Agency F2G, Limited Title Evaluation of the In vitro Activity of the Dihydroorotate Dehydrogenase Inhibitor F901318 against Rare Moulds Status Complete Period 2/2017 - 1/2018 Role Principal Investigator Grant Detail Funding Agency Research Across America Title Reference Laboratory for Research Across America Dermatophyte Study Status Complete Period 10/2014 - 10/2017 Role Principal Investigator Grant Detail Funding Agency Revolution Medicines Title Evaluation of the Investigational Amphotericin B Analogs for In Vivo Activity in Murine Models of Invasive Fungal Infections Status Complete Period 5/2015 - 4/2017 Role Co-Principal Investigator Grant Detail Funding Agency University of Alabama Birmingham Title University of Alabama Dermatophyte Study - Light Status Active Period 4/2015 - 3/2017 Role Principal Investigator Grant Detail Funding Agency University of Alabama Birmingham Title University of Alabama Dermatophyte - Polish Status Active Period 4/2015 - 3/2017 Role Principal Investigator Grant Detail

• Publications

  Abstract

  Wiederhold NP, Najvar LK, Jaramillo R, Olivo M,, Fukuda Y, Mitsuyama J, Olivo M, Patterson TF. The Novel Arylamidine T-2307 Demonstrates In vitro and In vivo Activity Against Candida auris San Francisco, CA; 2019 Jun. (Oral Presentation at ASM Microbe). Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Catano G, Patterson TF. Rezafungin is Efficacious Against Invasive Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Harboring the TR34/L98H Mutation San Francisco, CA; 2019 Jun. (Poster Presentation at ASM Microbe). Rybak J, Wiederhold NP, Fortwendel JR, Rogers PD. Discovery and Characterization of a Novel Mechanism of Clinical Triazole Antifungal Resistance: Mutations in the Aspergillus fumigatus HMG-CoA Reductase Gene, HMG1 Amsterdam, the Netherlands; 2019 Apr. (Oral Presentation at the 29th European Congress on Clinical Microbiology and Infectious Diseases). Wiederhold NP, McElmeel M, Patterson TF, Slayden RA, Cummings JE, Ramachandran V, Hameed S, Balasubramanian V. In Vitro Activity of BWC0977, a Novel Bacterial Topoisomerase Inhibitor, against Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates of the CDC Collection and Key Biodefense Pathogens Amsterdam, the Netherlands; 2019 Apr. (Poster Presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases). Rybak JM, Ge W, Wiederhold NP, Rogers PD, Fortwendel JR. Overexpression of cyp51A and cyp51B contribute to triazole resistance in clinical isolates of Aspergillus fumigatus from the United States Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Whaley SG, Wiederhold NP, Zhang Q, Yates CM, Schotzinger RJ, Garvey EP, Rogers PD. Contributions of the major C. glabrata triazole resistance determinants to the novel investigational tetrazoles VT-1598 and VT-1161 Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Wiederhold NP. Development and Evaluation of an Experimental Model of Invasive Candidiasis caused by Candida auris Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Rybak JM, Berkow EL, Dickens, Yates CM, Schotzinger, Garvey EP, Wiederhold NP, Rogers PD. Activity of investigational tetrazole antifungals VT-1161 and VT-1598 against a collection of characterized fluconazole resistant Candida parapsilosis clinical isolates Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morchhauser J, Yates CM, Schotzinger RJ, Garvey EP, Rogers PD. In vitro activities of the novel investigational tetrazoles VT-1598 and VT-1161 against azole-resistant strains and clinical isolates of C. albicans Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Rybak JM, Berkow EL, Dickens, Yates CM, Schotzinger, Garvey EP, Wiederhold NP, Rogers PD. Activity of investigational tetrazole antifungals VT-1161 and VT-1598 against a collection of clinical Candida tropicalis isolates with reduced susceptibility to fluconazole Amsterdam, the Netherlands; 2018 Jul. (Poster Presentation at the 20th Congress of the International Society of Human and Animal Mycoses). Ghannoum MA, Long LA, Larkin EL, Sherif R, Zohra Abidi F, Vasavada S, Borroto-Esoda K, Barat S, Angulo D, Wiederhold N. Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility between Resistant and Susceptibile Candida glabrata and C. albicans Isolates to SCY-078, a Novel Beta-D-glucan Synthase Inhibitor and Caspofungin? Atlanta, GA; 2018 Jun. (Poster Presentation at ASM Microbe 2018). Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Birch M, Law D, Patterson TF. The Orotomide F901318 is Efficacious in a Murine Model of Coccidioides Meningitis Madrid, Spain; 2018 Apr. (Oral Presentation at the 28th European Congress on Clinical Microbiology and Infectious Diseases). Rybak JM, Berkow EL, Dickens, Yates CM, Schotzinger, Garvey EP, Wiederhold NP, Rogers PD. Activity of the investigational tetrazole antifungal VT-1598 against Candida tropicalis and Candida parapsilosis isolates with reduced susceptibility to triazoles Providence, RI; 2018 Apr. (Poster Presentation at the 14th ASM Conference on Candida and Candidiasis). Whaley SG, Wiederhold NP, Zhang Q, Yates CM, Schotzinger RJ, Garvey EP, Rogers PD. Contributions of the Major C. glabrata Triazole Resistance Determinants PDR1, CDR1, PDH1, SNQ2, and UPC2A to the Novel Investigational Tetrazole VT-1598 Providence, RI; 2018 Apr. (Poster Presentation at the 14th ASM Conference on Candida and Candidiasis). Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morchhauser J, Yates CM, Schotzinger RJ, Garvey EP, Rogers PD. In vitro Activity of the Novel Investigational Tetrazole VT-1598 Against Azole-resistant C. albicans Clinical Isolates as well as Mutant Strains Representing Defined Mechanisms of Azole Resistance Providence, RI; 2018 Apr. (Poster Presentation at the 14th ASM Conference on Candida and Candidiasis). Wiederhold NP, Tran BH, Locke JB, Daruwala P, Bartizal K. Rezafungin (CD101) Demonstrates Potent In vitro Activity Against Aspergillus, including Azole-Resistant Aspergillus fumigatus and Cryptic Species Madrid, Spain; 2018 Apr. (Oral Presentation at the 28th European Congress on Clinical Microbiology and Infectious Diseases). Wiederhold NP, Tran BH, Locke JB, Daruwala P, Bartizal K. The Investigational Echinocandin CD101 Demonstrates Potent In vitro Activity against Aspergillus fumigatus, including Azole-Resistant Isolates Lisbon, Portugal; 2018 Feb. (Oral Presentation at the 8th Advances Against Aspergillosis Meeting). Rybak JM, Wiederhold NP, Dickens CM, Ge W, Rogers PD, Fortwendel JR. Non-cyp51A Mutation-Mediated Triazole Resistance in Clinical Isoaltes of Aspergillus fumigatus Liston, Portugal; 2018 Feb. (Poster Presentation at the 8th Advances Against Aspergillosis Meeting). Mele J, Wiederhold NP, Gibas C, Sutton DA, Wang Y, Vadlamudi K, Sanders C, McCarthy DI, Furmaga W, Fan H. ITS1 (Internal Transcribed Spacer) Primer Binding Site Polymorphism in Clinical Fungal Isolates Salt Lake City, UT; 2017 Nov. (Poster Presentation at the Association for Molecular Pathology Annual Meeting). Wiederhold NP, Jorgensen JH, McElmeel ML, Najvar LK, Catano G, Patterson TF. In vitro Activity of Fosfomycin Alone and Combined with Cefepime and Meropenem against Carbapenemase-Producing Gram-Negative Bacteria San Diego, CA; 2017 Oct. (Poster Presentation at IDWeek 2017). Gebremariam T, Alkhazraji S. Alqarhi A, Wiederhold NP, Shaw K, Patterson TF, Filler SG, Ibrahim AS. APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection San Diego, CA; 2017 Oct. (Poster Presentation at IDWeek 2017). Schwartz IS, Wiederhold NP, Patterson TF, Sigler L. Blastomyces helicus, a Cause of Pulmonary and Disseminated Blastomycosis in Immunocompromised Persons and Companion Animals in Western Canada and United States San Diego, CA; 2017 Oct. (Poster Presentation at IDWeek 2017). Bradford C, Pincus D, Hanson KE, Rychert J, Slechta ES, Beard M, Body B, Babady NE, Miranda E, Tang YW, Sutton DA, Wiederhold N, Curtis L, Turner S, Butler-Wu SM. Reproducibility of the New MALDI-TOF MS Database for Identification of Moulds, Mycobacterium and Nocardia New Orleans, LA; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Rychert J, Slechta ES, Barker A, Miranda E, Babady E, Tang YW, Wiederhold N, Sutton D, Hanson K. Multi-Center Evaluation of a New MALDI-TOF MS Database for the Identification of Medically Important Moulds New Orleans, LA; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Catano G, Sullivan SM, Hopkins AM, Smith LR, Patterson TF. The Novel Antifungal VL-2397 Demonstrates Efficacy in an In vivo Model of Invasive Candidiasis Caused by Wild-Type and Multi-Drug Resistant Candida glabrata New Orleans, LA; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Wiederhold NP, Tran BH, Patterson H, Yates CM, Schotzinger RJ, Garvey EP. The Novel Cyp51 Inhibitor VT-1598 Demonstrates Potent In Vitro Activity Against Candida and Cryptococcus Species New Orleans, LA; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Wiederhold NP, Tran BH, Patterson H, Yates CM, Schotzinger RJ, Garvey EP. The Novel Cyp51 Inhibitor VT-1598 Demonstrates Potent In Vitro Activity Against Endemic Fungi, Aspergillus, and Rhizopus New Orleans, LA; 2017 Jun. (Poster Presentation at ASM Microbe 2017). Gebremariam T. Alkhazraji S, Baldin C, Kovanda L, Wiederhold N, Ibrahim AS. Isavuconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis Vienna, Austria; 2017 Apr. (Poster Presentation at the 27th European Congress of Clinical Microbiology and Infectious Diseases). 135. Slechta ES, Body B, Babady NE, Miranda E, Tang YW, Sutton DA, Wiederhold NP, Butler-Wu S. Identification of a Characterized Challenge Set of Moulds, Mycobacterium and Nocardia Strains Using the New bioMerieux VITEK MS v3.0 Database Vienna, Austria; 2017 Apr. (Poster Presentation at the 27th European Congress of Clinical Microbiology and Infectious Diseases). Wiederhold NP, Sutton DA, Sanders C, Mele J, Gibas CFC, Fan H. Prevalence of Different Aspergillus Species in the United States: 1 Year Surveillance Study of Clinical Isolates from a Reference Laboratory Vienna, Austria; 2017 Apr. (Poster Presentation at the 27th European Congress of Clinical Microbiology and Infectious Diseases). Garvey E, Sharp A, Warn P, Wiederhold N, Yates C, Schotzinger R. VT-1598 is a Highly Potent Inhibitor of Cryptococcus species In Vitro and In Vivo Foz do Iguacu, Brazil; 2017 Mar. (Poster presentation at the 10th International Conference on Cryptococcus and Cryptococcosis). Wiederhold NP, Dorsey S, Patterson TF. Clinically Achievable Concentrations of Posconazole Before and After the Availability of the Delayed Release Tablet and Intravenous Formulations Santiago, Chile; 2016 Nov. (Poster Presentation at the XIX Immuncompromised Host Society Symposium, XIV INFOCUS Meeting). Rybak JM, Dickens CM, Wiederhold NP, Fortwendel JR, Rogers PD. Novel Mechanisms of Triazole Resistance in Clinical Aspergillus fumigatus Isolates through Next-Generation Sequencing Hollywood, FL; 2016 Oct. (Poster Presentation at the American College of Clinical Pharmacy Annual Meeting). Rybak JM, Berkow EL, Zhang Q, Dickens CM, Wiederhold NP, Palmer GE, Rogers PD. Revealing Novel Mechanisms of Fluconazole Resistance in Clinical Candida tropicalis Isolates through Next-Generation Sequencing and Heterologous Overexpression in Candida albicans Hollywood, FL; 2016 Oct. (Poster Presentation at the American College of Clinical Pharmacy). Thompson GR, Krois C, Affolter V, Everett A, Varjonen K, Sharon V, Singapuri A, Dennis M, Fedor D, Wiederhold NP, Gelli A, Napoli J, White S. Retinoic Acid is not Involved in Fluconazole Induced Alopecia: Evaluation in a Human Cohort and Rat Model New Orleans, LA; 2016 Oct. (Poster Presentation at IDWeek 2016). Yu X, Koshy S, Aloum O, Baden L, Marty F, Wiederhold N, Koo S. In vitro Volatile Metabolite Signatures of Common Pathogenic Fusarium Species New Orleans, LA; 2016 Oct. (Poster Presentation at IDWeek 2016). Yu X, Koshy S, Aloum O, Baden L, Marty F, Wiederhold N, Koo S. Examining the In vitro Volatile Metabolite Profile of Pathogenic Scedosporium and Lomentospora Species New Orleans, LA; 2016 Oct. (Poster Presentation at IDWeek 2016). Yu X, Al-Kateb M, Aloum O, Baden LR, Marty FM, Manalakos SZ, Wiederhold NP, Chowdhary A, Koo S. In Vitro Volatile Metabolite Signature of Common Pathogenic Mucorales Boston, MA; 2016 Jun. (Poster Presentation at ASM Microbe 2016). Soto E, Richey C, Reichley SR, Stevens B, Kenelty K, Lewis Janiee, Byrne B, Wiederhold NP, Stacy BA, Waltzek TB, Sheley MF, Murphy B, Camus A, Griffin MJ. Genetic Diversity of Veronaea botryosa and Development of Infectious Challenge Model for Systemic Phaeohyphomycosis in White Sturgeon, Acipenser transmontanus Jackson Hole, WY; 2016 Jun. (Oral Presentation at the 57th Western Fish Disease Workshop, AFS Fish Health Section Meeting, and 22). Thompson GR III, Barker BM, Wiederhold NP. Evaluation of In Vitro Amphotericin B and Triazole Activity Against Coccidioides Species from U.S. Institutions Boston, MA; 2016 Jun. (Poster Presentation at ASM Microbe 2016). Kapoor R, Wiederhold N, Najvar LK, Patterson TF, Chang W. A Rapid and Sensitive (1→3)-β-D-Glucan Microfluidic Assay for Early Detection of Invasive Aspergillosis Infections in a Murine Model Boston, MA; 2016 Jun. (Poster Presentation at ASM Microbe 2016). Fothergill AW, Law D, Birch M, Wiederhold NP. The Novel Orotomide F901318 Demonstrates Potent In vitro Antifungal Activity against Lomentospora and Scedosporium Species Amsterdam, The Netherlands; 2016 Apr. (Poster Presentation at the 26th European Congress of Clinical Microbiology and Infectious Diseases). Wiederhold NP, Fothergill AW, Patterson TF, Sutton DA. Review of Aspergillus spp. Collected from Brain, Cerebral Spinal Fluid, Vitreous Fluid, and Corneas in the United States Manchester, UK; 2016 Mar. (Poster Presentation at the 7th Advances Against Aspergillosis Meeting). Lindner JR, Vadlamudi K, Wiederhold NP, Wang Y, Sutton DA, Fothergill AW, Garcia Gil V, Furmaga W, Fan H. Detection of Aspergillus fumigatus cyp51AGene Mutations in Clinical Azole Resistant Isolates Austin, TX; 2015 Nov. (Poster Presentation at the Association for Molecular Pathology Annual Meeting). Lindner JR, Wang Y, Vadlamudi K, Sutton DA, Wiederhold NP, Fothergill AW, Sanders C, McCarthy DI, Furmaga W, Fan H. Molecular Identification of Clinical Fungal Isolates by Sequencing Multiple Gene Targets Austin, TX; 2015 Nov. (Poster Presentation at the Association for Molecular Pathology Annual Meeting). Fothergill AW, McCarthy DI, Lindner J, Fan H, Wiederhold NP. Molecular Identification of Yeast: Gold Standard or Fool?s Gold? Lisbon, Portugal; 2015 Oct. (Poster Presentation at the 2015 Trends in Medical Mycology Meeting). Fothergill AW, Trippy S, Wiederhold NP. Influence of Microtitre Tray Platic Type on Azole Minimum Inhibitory Concentrations Against Candida and Aspergillus Species Lisbon, Portugal; 2015 Oct. (Poster Presentation at the 2015 Trends in Medical Mycology Meeting). Wiederhold NP, Garcia Gil V, Lindner J, Sanders C, Fan H, Sutton DA, Fothergill AW. Evaluation of Cyp51 Mechanisms of Azole Resistance in Aspsergillus fumigatus Isolates from the United States Lisbon, Portugal; 2015 Oct. (Poster Presentation at the 2015 Trends in Medical Mycology Meeting). Proniuk S, Wiederhold NP, Patterson TF Cushion MT, Krysan DJ, Green J, Koselny K, Zukiwski A. AR-12, Lead Compound of a Potential New Class of Antifungal Agents San Diego, CA; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Albataineh MT, Fothergill AW, Wiederhold NP. Emergence of Azole and Echinocandin Multi-drug Resistant Candida glabrata: A Reference Laboratory Experience San Diego, CA; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Garvey EP, Hoekstra WJ, Schotzinger RJ, Fothergill AW, Wiederhold NP, Warrilow AGS, Parker JE, Kelley DE, Kelly SL. VT-1129 Binds Potently and Selectively to Recombinant Cryptococcal CYP51 Consisten with its Potent In Vitro Anti-cryptococcal Activity San Diego, CA; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Najvar LK, Galgiani JN, Nix DE, Bocanegra R, Patterson TF, Wiederhold NP. Combination Therapy with VFS1 and Caspofungin Improves Survival in Experimental Invasive Aspergillosis San Diego, CA; 2015 Sep. (Oral Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Fothergill AW, Wiederhold NP, Sibley G, Kennedy A, Oliver J, Birch M, Law D. Spectrum of Activity of F901318, the First Agents from the Newly Discovered Orotomide Class of Antifungals San Diego, CA; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Wiederhold NP, Jorgensen JH, Boakes S, Collins MS, McElmeel M, Cushion MT, Patterson TF. Antibacterial Activity of Novel Polymyxin B Derivatives Against Gram-negative Bacteria and Initial Toxicity Assessment San Diego, CA; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Musumechi R, Wiederhold NP, Jorgensen JH, Patterson TF, Bulbarelli A, Sancini G, Pace A, Palumbo Piccionello A, Fortuna CG, Cocuzza CE. Preclinical Development of MiBIECT, a New Oxadiazolyl-Oxazolidinone Compound Active Against Gram-positive Cocci; 2015 Sep. (Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Gebremariam T, Wiederhold NP, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS. Prophylactic Treatment of Pulmonary Mucormycosis with VT-1161 Using Immunosuppressed Mice San Diego, CA; 2015 Sep. (Oral Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy). Wiederhold NP, Ibrahim AS, Warn P, Najvar LK, Wickes BL, Kadosh D, Kirkpatrick WR, Filler S, Patterson TF. A U.S. National Institutes of Health Resource for the In Vivo Assessment of Novel Antifungal Compounds and Diagnostic Assays Melbourne, Australia; 2015 May. (Poster Presentation at the 19th Int. Congress. of the Int. Society Human and Animal Mycoses). Najvar LK, Wiederhold NP, Alimardanov A, Cradock J, Xu X, Behnke M, Ottinger EA, Hoekstra WJ, Garvey EP, Brand SR, Schotzinger RJ, Bocanegra R, Kirkpatrick WR, Patterson TF. VT-1129 Demonstrates Potent In Vivo Activity in Mice against Cryptococcal Meningitis when Administered Alone or when Combined with Amphotericin B Melbourne, Australia; 2015 May. (Poster Presentation at the 19th Int. Congress. of the Int. Society Human and Animal Mycoses). Bocanegra R, Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity Against Echinocandin Resistant Candida glabrata Melbourne, Australia; 2015 May. (Oral Presentation at the 19th Int. Congress. of the Int. Society Human and Animal Mycoses). Long L, Isham N, Ghannoum MA, Garvey EP, Brand SR, Degenhardt TP, Hoekstra WJ, Schotzinger RJ, Fothergill AW, Wiederhold NP. High In Vitro Potency of the Clinical Investigational Agent VT-1161 against Clinical Isolates of Candida spp Copenhagen, Denmark; 2015 Apr. (Poster Presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases). Wiederhold NP, Najvar LK, Alimardanov A, Cradock J, Xu X, Behnke M, Ottinger EA, Hoekstra WJ, Garvey EP, Brand SR, Schotzinger RJ, Bocanegra R, Kirkpatrick WR, Patterson TF. The Novel Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In vivo Activity against Cryptococcal Meningitis with a Loading/Maintenance Dosing Regimen Copenhagen, Denmark; 2015 Apr. (Poster Presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases). Gebremariam T, Wiederhold NP, Fothergill AW, Patterson T, Filler S, Ibrahim AS. VT-1161 Protects Immunosuppressed Mice from Rhizopus oryzae Infection Copenhagen, Denmark; 2015 Apr. (Oral Presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases). Vipulanandan G, Herrera ML, Wiederhold NP, Wickes BL, Kadosh D. Dynamics of Mixed Candida Species Biofilms in Response to Antifungals Boston, MA; 2015 Mar. (Oral Presentation at the 2015 Int. Assoc. of Dental Research/American Association of Dental Research). Lindner JR, Wiederhold NP, Sutton DA, Sanders C, Vadlamudi K, Fan H. Molecular Identification of Rhizopus arrhizus and Rhizopus delemar by Internal Transcribed Spacer (ITS) Sequence National Harbor, MD; 2014 Nov. (Poster Presentation at the Association for Molecular Pathology 2014 Annual Meeting). Maincent J, Huang S, Najvar LK, Kirkpatrick WR, Patterson TF, Wiederhold NP, Williams RO, III. Enteric Polymer and Hydrophilic Additive Processed by Hot-Melt Extrusion to Improve Bioavailability of Itraconazole San Diego, CA; 2014 Nov. (Poster Presentation at the 2014 American Association of Pharmaceutical Scientists Annual Meeting). Lindner JR, Sutton DA, Wiederhold NP, Fothergill AW, Wickes BL, Sanders C, McCarthy DI, Wang Y, Vadlamudi K, Fu J, Furmaga W, Fan H. Validation of a Molecular Identification Assay for Fusarium Species in a CLIA Certified Molecular Diagnostics Laboratory National Harbor, MD; 2014 Nov. (Poster Presentation at the Association for Molecular Pathology 2014 Annual Meeting). Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF. The Investigational Agent E1210 is Effective in the Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans Washington, DC; 2014 Sep. (Late Breaker Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Che). Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP. Detection of Triazole Resistance among Candida Species by Matrix Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) Washington, DC; 2014 Sep. (Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy). Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF. The Novel Arylamidine T-2307 is Efficacious Against Invasive Candidiasis Caused by an Echinocandin Resistant Candida albicans Washington, DC; 2014 Sep. (Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy). Fothergill AW, Cushion MT, Collins MS, Kirkpatrick WR, Najvar LK, Patterson TF, Wiederhold NP. Antifungal and Anti-Pneumocystis Activity of the Novel Arylamidine T-2307 Washington, DC; 2014 Sep. (Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy). Najvar LK, Wiederhold NP, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF. Isavuconazole is Effective for the Treatment of Experimental Cryptococcal Meningitis Washington, DC; 2014 Sep. (Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy). Fothergill AW, McCarthy DI, Sutton DA, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Wiederhold NP. The Fungal Cyp51 Inhibitor VT-1161 Demonstrates In Vitro Synergy with Tacrolimus against Aspergillus spp. And Members of the Order Mucorales Washington, DC; 2014 Sep. (Oral Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy). Deravin SS, Parta M, Jancel T, Sutton DA, Wiederhold NP, Shea YR, Holland SM, Malech HL, Zelazny AM. Invasive Basidiomycete Phellinus/Inonotus spp. Infections in Chronic Granulomatous Disease Boston, MA; 2014 May. (Poster Presentation at the American Society for Microbiology Annual Meeting). Najvar LK
  Wiederhold NP
  Alimardanov A
  Cradock J
  Xin X
  Behnke M
  Ottinger EA
  Hoekstra W
  Garvey EP
  Brand SR
  Schotzinger RJ
  Moore WR
  Bocanegra R
  Kirkpatrick WR
  Patterson TF. The Novel Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In vivo Activity against Cryptococcal Meningitis with an Improved Formulation Amsterdam, the Netherlands; 2014 May. (Poster Presentation at the 9th International Conference on Cryptococcus and Cryptococcosis). Wiederhold NP, Fothergill AW, McCarthy DI, Sanders C, Sutton DA. Evaluation of the In vitro Potency of Itraconazole, Voriconazole, and Posaconazole and against Rare Aspergillus Species Barcelona, Spain; 2014 May. (Poster Presentation at the 24th European Congress of Clinical Microbiology and Infectious Diseases). Fothergill, AW, McCarthy DI, Wiederhold NP, Tavakkol A. Luliconazole Demonstrates Potent In Vitro Activity Against Dermatophytes Recovered from Patients with Onychomycosis Denver, CO; 2014 Mar. (Poster Presentation at the American Association of Dermatology Annual Meeting). Wiederhold NP, Fothergill AW, Cognata Smith C, Kaur M, Gupta AK. Luliconazole is Significantly More Potent In Vitro than Naftifine Against Clinical Dermatophyte and Candida albicans Isolates Denver, CO; 2014 Mar. (Poster Presentation at the American Association of Dermatology Annual Meeting). Wiederhold NP, Fothergill AW, McCarthy DI, Sanders C, Sutton DA. Evaluation of the In Vitro Potency of Itraconazole, Voriconazole, and Posaconazole and Resistance in Aspergillus Isolates from the United States Madrid, Spain; 2014 Mar. (Poster Presentation at the 6th Advances Against Aspergillosis Meeting). Monnin V
  Girard V
  Arend S
  Celliere B
  Arsac M
  Pincus D
  Wilkey K
  Mikkhailov V
  Sutton D
  Wiederhold N. Rapid Identification of Mould Species from Agar Cultures by MALDTI-TOF Mass Spectrometry San Diego, CA; 2014 Mar. (Poster Presentation at the Mass Spectrometry: Applications to the Clinical Laboratory 2014 US Meetin).

  Book Chapter

  Gibas CFC, Wiederhold NP. Medically Significant Fungi (Chapter 27). In: Mahon CR, Lehman DC, eds. Textbook of Diagnostic Microbiology. 2019. Seyedmousavi S, Wiederhold NP, Ebel F, Hedayati MT, Rafati H, Verweij P. Antifungal Use in Veterinary Practice and Emergence of Resistance. In: Emerging and Epizootic Infections in Animals. In: Seyedmousavi S, de Hoog GS, Guillot J, Verweij PE eds. Emerging and Epizootic Infections in Animals. 2018. Reidarson TH, Garcia-Parraga D, Wiederhold N. Marine Mammal Mycoses (Chapter 19). In: Dierauf LA, Gulland F, Whitman KL eds. CRC Handbook of Marine Mammal Medicine, 3rd Edition. 2018. Wiederhold NP. Advanced Molecular Diagnosis of Fungal Infections (Chapter 43). In: Tang YW, Stratton C. eds. Advanced Techniques in Diagnostic Microbiology. 2018. Zhang SZ, Wiederhold NP. Yeasts. In: Hayden RT, Wolk DM, Carroll KC, Tang YW, eds. Microbiol Spectrum. 2016. Wiederhold NP, Sutton DA. What?s Old is New: Recognition of New Fungal Pathogens in the Era of Phylogenetics and Changing Taxonomy and Implications for Medical Mycology. In: Dewei L, ed. Biology of Microfungi. 2016. Wiederhold NP
  Patterson TF. Antifungal Therapy. In: Schlossberg D, ed. Clinical Infectious Diseases. 2nd Ed. Cambridge, United Kingdom: Cambridge University Press; 2015. p. 1344-1352.

  Journal Article

  Babiker A, Gupta N, Gibas FC, Wiedehrold NP, Sanders C, Mele J, Fan H, Iovleva A, Haidar G, Fernandes C. Rasamsonia sp: an Emerging Infection Amongst Chronic Granulomatous Disease Patients. A Case of Disseminated Infection by a Putatively Novel Rasamsonia argillacea Species Complex Involving the Heart Med Mycol Case Rep 2019 Jan;24:54-57. Thompson GR, Krois CR, Affolter VK, Everett AD, Varjonen EK, Sharon V, Singapuri A, Dennis M, McHardy I, Sik H, Fedor DM, Wiederhold NP, Aaron P, Gelli A, Napoli JL, White SD. Fluconazole-Induced Alopecia: Examination in an Animal Model and Human Cohort Antimicrob Agents Chemother 2019 Jan;63:e01384-18. Hernandez-Restrepo M, Bezerra JDP, Tan YP, Wiederhold N, Crous PW, Guarro J, Gene J. Re-Evaluation of Mycoleptodiscus Species and Morphologically Similar Fungi Persoonia 2019 Jan;42:205-207. Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, Garvey EP, Yates CM, Schotzinger RJ, Catano G, Patterson TF. The Fungal Cyp51 Specific Inhibitor VT-1598 Demonstrates In vitro and In vivo Actvity against Candida auris Antimicrob Agents Chemother 2019 Jan;63:e02233-18. Schwartz IL, Wiederhold NP, Patterson TF, Hanson KE, Sigler L. Blastomyces helicus, a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and United States Clin Infect Dis 2019 Jan;68:188-195. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bleasdale SC, Danziger L. Development of High-Level Echinocandin Resistance in a Patient with Recurrent Candida auris Candidemia Secondary to Chronic Candiduria Open Forum Infect Dis (In Press) 2019 Jan;. Rybak J, Ge W, Wiedehrold N, Parker J, Kelly S, Rogers PD, Fortwendel J. Mutations in hmg1: Challening the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus mBio 2019 Jan;10:e00437-19. Parambeth JC, Lawhon SD, Mansell J, Wu J, Clark SD, Sutton D, Gibas C, Wiederhold NP, Myers AN, Johnson MC, Levine GJ, Schlemmer S, Ruoff C, Isaiah A, Creevy KE. Gastrointestinal Pythiosis with Concurrent Presumptive Gastrointestinal Basidiobolomycosis in a Boxer Dog Vet Clin Path 2019 Jan;48:83-88. Cornely OA, Alastruey-Izquierod A, Arenz D, et al. For the Mucormycosis ECMM MSG Global Guidelines Writing GroupGlobal. Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation with the Mycoses Study Group Education and Research Consortium Lancet Infect Dis (In Press) 2019 Jan;. Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morschhauser J, Yates CM, Hoekstra WJ, Schotzinger RJ, Garvey EP, Rogers PD. In vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans Antimicrob Agents Chemother 2019 Jan;63:e00341-19. Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M. In vitro Activity of Isavuconazole versus Opportunistic Pathogens from Two Mycology Reference Laboratories Antimicrob Agents Chemother 2018 Jan;62:e01230-18. Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra W, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF. In vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the use of a Loading Dose-Maintenance Dose Administration Strategy Antimicrob Agents Chemother 2018 Jan;62:e01315-18. Rainwater KL, Wiederhold NP*, Sutton DA, Garner MM, Maguire C, Sanders S, Gibas C, Cano JF, Guarro J, Stchigel AM. Novel Paranannizziopsis Species in a Wagler?s Viper (Tropidolaemus wagleri), Tentacled Snakes (Erpeton tentaculatum), and a Rhinoceros Snake (Rhyncophis boulengeri) in a Zoological Collection Med Mycol (In Press) 2018 Jan;. Ilieva V, Thomas E, Walraven C, Sutton D, Wiederhold N, Lee S. Lung Abscess due to Aspergillus lentulus in a Patient with Granulomatosis with Polyangiitis: Case and Review of the Literature Infect Dis Clin Pract 2018 Jan;26:100-105. Sanchez AR, Anjan S, Martinez OV, Lekakis LJ, Beitinjaneh A, Camargo JF, Gibas CFC, Sanders CJ, Wiederhold NP, Abbo LM. Invasive Rhinosinusitis caused by Lasiodiplodia theobromae in an Allogeneic Hematopoietic Cell Transplant Recipient: Case Report and Review of Literature Mycopathologia 2018 Jan;183:841-845. Wiederhold NP, Shubitz LF, Najvar LK, Jaramillo R, Olivo M, Catano G, Trinh HT, Yates CM, Schotzinger RJ, Garvey EP, Patterson TF. The Novel Fungal Cyp51 Inhibitor VT-1598 is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis Antimicrob Agents Chemother 2018 Jan;62:e02258-17. Rychert J, Slechta ES, Barker AP, Miranda E, Babady NE, Tang YW, Gibas C, Wiederhold N, Sutton D, Hanson KE. Multi-Center Evaluation of the VITEK MS v3.0 System for the Identification of Filamentous Fungi J Clin Microbiol 2018 Jan;56:e01353-17. Wall G, Chaturvedi AK, Wormley FL, Wiederhold NP, Patterson HP, Patterson TF, Lopez-Ribot JL. Screening a Repurposing Library for Inhibitors of Multi-Drug Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development Antimicrob Agents Chemother 2018 Jan;62:e01084-14. Autmizguine J, Tan S, Cohen-Wolkowiez, Cotten CM, Wiederhold N, Goldberg RN, Adams-Chapman I, Stoll B, Smith PB, Benjamin DK. Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis Pediatr Infect Dis J 2018 Jan;37:923-929. Desoubeaux G, Debourgogne A, Wiederhold NP, Zaffino M, Sutton D, Burns RE, Frasca S, Hyatt MW, Cray C. Epidemiological Insights for Diseased Sharks Infected with Fungi Belonging to the Fusarium soloni Species Complex Med Mycol 2018 Jan;56:591-601. Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Birch M, Law D, Rex JH, Catano G, Patterson TF. The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis Antimicrob Agents Chemother 2018 Jan;62:e00999-18. Wiederhold NP, Locke JB, Daruwala P, Bartizal K. Rezafungin (CD101) Demonstrates Potent In vitro Activity against Aspergillus, including Azole-Resistant A. fumigatus Isolates and Cryptic Species J Antimicrob Chemother 2018 Jan;73:3063-3067. Siqueira JPZ, Sutton D, Gene J, Garcia D, Wiederhold N, Guarro J. Species of Aspergillus section Aspergillus from Clinical Samples in USA Med Mycol 2018 Jan;56:541-550. Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EQ, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, WR Kirkpatrick, Patterson TF. The Fungal Cyp-51 Inhibitor VT-1129 is Efficacious in an Experimental Model of Cryptococcal Meningitis Antimicrob Agents Chemother 2018 Jan;62:e01071-18. Spitzer M, Wiederhold N. Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels J Lower Genit Tract Dis 2018 Jan;22:152-158. Siqueira JPZ, Wiederhold N, Gene J, Garcia D, Almeida MTG, Guarro J. Cryptic Aspergillus from Clinical Samples in the USA and Description of a new Species in Section Flavipedes Mycoses 2018 Jan;61:814-825. Vipulanandan G, Herrera M, Wiederhold NP, Li X, Mintz J, Wickes BL, Kadosh D. Dynamics of Mixed Candida Species Biofilms in Response to Antifungals J Dent Res 2018 Jan;97:91-98. Wiederhold NP, Patterson H, Tran BH, Yates C, Schotzinger RJ, Garvey EP. The Fungal Specific Cyp51 Inhibitor VT-1598 Demonstrates In vitro Activity against Candida and Cryptococcus Species, Endemic Fungi, including Coccidioides Species, Aspergillus Species, and Rhizopus arrhizus J Antimicrob Chemother 2018 Jan;73:404-408. Valenzuela-Lopez N, Cano-Lira JF, Guarro J, Sutton DA, Wiederhold N, Crous PW, Stchigel AM. Coelomycetous Dothideomycetes with Emphasis on the Families Cucurbitariaceae and Didymellaceae Stud Mycol 2018 Jan;90:1-69. Schwartz IS, Sanche E, Wiederhold NP, Patterson TF, Sigler L. Emergomyces canadensis is a New Cause of Fatal Systemic Disease in Humans in North America Emerg Infect Dis 2018 Jan;24:758-761. Soto E, Richey C, Reichley SR, Stevens B, Kenelty K, Lewis Janiee, Byrne B, Wiederhold NP, Stacy BA, Waltzek TB, Sheley MF, Murphy B, Camus A, Griffin MJ. Diversity of Veronaea botryosa from different hosts and evaluation of laboratory challenge models for phaeohyphomycosis in Acipenser transmontanus Dis Aquat Org 2017 Jun;7:7-18. Rybak J, Dickens C, Parker J, Caudle K, Manigaba K, Whaley S, Nishimoto A, Luna-Tapia A, Roy S, Zhang Q, Barker K, Palmer G, Sutter T, Homayouni R, Wiederhold N, Kelly S, Rogers PD. Loss of C-5 Sterol Desaturate Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis Antimicrob Agents Chemother 2017 Jan;61:e06651-17. Warrilow A, Parker J, Price C, Garvey E, Hoekstra W, Schotzinger R, Wiederhold N, Nes D, Kelly D, Kelly S. The Tetrazole VT-1161 is a Potent Inhibitor of Trichophyton rubrum through its Inhibition of T. rubrum CYP51 Antimicrob Agents Chemother 2017 Jan;61:e00333-17. Gebramariam T, Alkhazraji S, Lin L, Wiederhold N, Garvey E, Hoekstra W, Schotzinger R, Patterson T, Filler S, Ibrahim S. Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection Antimicrob Agents Chemother 2017 Jan;61:e00390-17. Siquira PZ, Sutton D, Gene J, Garcia D, Wiederhold N, Peterson S, Guarro J. Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov J Clin Microbiol 2017 Jan;55:947-958. Hardin JS, Sutton DA, Wiederhold NP, Mele J, Goyal S. Fungal Keratitis Secondary to Trametes betulina: A Case Report and Review of Literature Mycopathologia 2017 Jan;182:755-759. Wiederhold NP, Law D, Birch M. The Dihydroorotate Dehydrogenase Inhibitor F901318 has Potent In vitro Activity against Scedosporium Species and Lomentospora prolificans J Antimicrob Chemother 2017 Jan;72:1977-1980. Giraldo A, Gene J, Sutton DA, Wiederhold N, Guarro G. New Acremonium-like Taxa in the Bionecriaceae and Plectosphaerellaceae Mycol Prog 2017 Jan;16:349-368. Thompson GR, Barker B, Wiederhold N. Large Scale Evaluation of In vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from United States Institutions Antimicrob Agents Chemother 2017 Jan;61:e02634-16. Hong G, White M, Lechtzin N, West NE, Miller H, Lee R, Lovari RJ, Massire C, Blyn LB, Liang X, Sutton DA, Fu J, Wickes BL, Wiederhold NP, Zhang SX. Fatal Disseminated Rasamsonia Infection in Cystic Fibrosis Post-Lung Transplantation J Cystic Fib 2017 Jan;16:e3-e7. Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Catano O, Pizzini J, Patterson TF. The Oral Glucan Synthase Inhibitor SCY-078 is Effective in an Experimental Murine Model of Invasive Candidiasis caused by Wild-type and Echinocandin Resistant Candida glabrata J Antimicrob Chemother 2017 Jan;73:448-451. Guevara-Suarez M, Sutton DA, Gene J, Garcia D, Wiederhold N, Guarro J, Cano-Lira JF. Four New Species of Talaromyces from Clinical Sources Mycoses 2017 Jan;60:651-662. Basaran S, Karabicak N, Simsek YS, Wiederhold NP, Safak S, Saribuga A, Sutton DA, Bingol Z, Cagatay A, Ozsut H, Kilicaslan Z, Eraksoy H. A Case of Coccidioidomycosis in Turkey Imported from the United States of America Mikrobiyol Bul 2017 Jan;51:183-190. Valenzuela-Lopez N, Sutton D, Cano-Lira J, Paredes K, Wiederhold N, Guarro, J, Stchigel A. Coelomycetous Fungi in the Clinical Setting: Morphological Convergence and Cryptic Diversity J Clin Microbiol 2017 Jan;55:552-567. Gebremariam T, Alkhazraji S, Baldin C, Kovanda L, Wiederhold N, Ibrahim A. Prophylaxis with Isavuconazole or Posaconazole Protect Immunosuppressed Mice from Pulmonary Mucormycosis Antimicrob Agents Chemother 2017 Jan;61:e02589-16. Stchigel AM, Sutton DA, Cano-Lira JF, Wiederhold N, Guarro J. New Additions to the Genus Spiromastigoides (Eurotiomycetes, Ascomycota) Mycopathologia 2017 Jan;182:967-978. Hajjar J, Restrepo A, Javeri H, Wiederhold NP, Papanastassiou A, Patterson TF. Multiple Brain Abscesses caused by Trichosporon inkin in a Patient with X-linked Chronic Granulomatous Disease (CGD) Successfully Treated with Antifungal Therapy J Clin Immunol 2017 Jan;37:519-523. Hyatt MW, Wiederhold NP, Hope WW, Stott KE. Pharmacokinetics of Orally Administered Voriconazole in African Penguins (Spheniscus demersus) after Single and Multiple Doses J Zoo Wildl Med 2017 Jan;48:352-362. Maincent J, Najvar LK, Kirkpatrick WR, Huang S, Patterson TF, Wiederhold NP, Peters JI, Williams RO. Modified Release Itraconazole Amorphous Solid Dispersion to Treat Aspergillus fumigatus: Importance of Animal Model Selection Drug Dev Ind Pharm 2016 Sep;:1-35. Gebremariam T, Wiederhold N, Alqarihi, Uppuluri P, Azzie N, Edwards J Jr., Ibrahim A. Mono or Combination Therapy of Isavuconazole and Micafungin for Treating Murine Mucormycosis J Antimicrob Chemother 2016 Jan;72:462-466. Wiederhold NP, Garcia Gil V, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, Sanders C, Fan H, Fothergill AW, Sutton DA. First Detection of TR34/L98H and TR46/Y121F/T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States J Clin Microbiol 2016 Jan;54:168-171. Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF. The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity Against Echinocandin Resistant Candida glabrata J Antimicrob Chemother 2016 Jan;71:692-695. Sandoval-Denis M, Guarro J, Cano-Lira JF, Sutton DA, Wiederhold NP, de Hoog GS, Abbott SP, Decock C, Sigler L, Gene J. Phylogeny and Taxonomic Revision of Microascaceae with Emphasis on Synnematous Fungi Stud Mycol 2016 Jan;83:193-233. Wiederhold NP, Patterson TF, Srinivasan A, Fothergill AW, Ramasubramanian AK, Lopez-Ribot JL. Repurposing Auranofin as an Antifungal: In Vitro Activity against a Variety of Medically Important Fungi Virulence 2016 Jan;8:138-142. Sanchis M, Capilla J, Castanheira M, Martin-Vincente A, Sutton DA, Fothergill AW, Wiederhold NP, Guarro J. Voriconazole MICs are Predictive for Treatment Outcome of Murine Infection by Candida glabrata Int J Antimicrob Agents 2016 Jan;47:286-288. Stewart E, Waldman S, Sutton DA, Sanders C, Lindner J, Fan H, Wiederhold NP, Thompson GR. Ustilago echinata: Infection in a Mixed Martial Artist Following an Open Fracture Mycopathologia 2016 Jan;181:311-314. Relich RF, Schmitt BH, Koehlinger J, Wiederhold NP, May M. Schwanniomyces etchellsii: An Unusual Cause of Fungemia in a Patient with Cholecystitis Diagn Microbiol Infect Dis 2016 Jan;84:221-222. Reedy J, Negoro P, Feliu M, Lord A, Khan N, Lukason D, Wiederhold N, Tam J, Mansour M, Patterson T, Vyas J. The Carbohydrate Lectin Receptor, Dectin-1, Mediates Immune Response to Exserohilum rostratum Infect Immun 2016 Jan;83:e00903-16. Zen-Siqueira JP, Sutton DA, Garcia D, Gene J, Thomson P, Wiederhold N, Guarro J. Species Diversity of Aspergillus section Versicolores in Clinical Samples and Antifungal Susceptibility Fungal Biol 2016 Jan;120:1458-1467. White PL, Wiederhold N, Loeffler J, Najvar L, Melchers W, Herrera M, Bretagne S, Wickes B, Kirkpatrick W, Barnes RA, Donnelly JP, Patterson TF. A Comparison of Non-Culture Blood-Based Tests Available to Aid in the Diagnosis of Invasive Aspergillosis in an Animal Model J Clin Microbiol 2016 Jan;54:960-966. Kadosh, D
  Najvar, LK
  Bocanegra, R
  Olivo, M
  Kirkpatrick, WR
  Wiederhold, N
  Patterson, T. Effect of antifungal treatment in a diet-based murine model of disseminated candidiasis acquired via the gastrointestinal tract Antimicrob Agents Chemother 2016 Jan;60:6703-6708. Sandoval-Denis M, Gene J, Sutton DA, Wiederhold NP, Cano JF, Guarro J. New Species of Cladosporium Associated with Human and Animal Infections Persoonia 2016 Jan;36:281-298. Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, Livermore J, Bromley MJ, Wiederhold NP, Hope W, Kennedy AJ, Law D, Birch M. F901318 Represents a New Class of Antifungal Drugs that Inhibit Dihydroorotate Dehydrogenase Proc Natl Acad Sci 2016 Jan;113:12809-12814. Fothergill AW, McCarthy DI, Albataineh MT, SAnders C, McElmeel M, Wiederhold NP. The Effects of Treated or Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species J Clin Microbiol 2016 Jan;54:734-738. Ghannoum M, Chaturvedi V, Diekema D, Ostrosky-Zeichner L, Rennie R, Walsh T, Wengenack N, Fothergill A, Wiederhold N. Multilaboratory Evaluation of In Vitro Susceptibility Testing of Dermatophytes for ME1111 J Clin Microbiol 2016 Jan;54:662-665. Koselny K, Green J, DiDone L, Halterman J, Fothergill A, Wiederhold N, Patterson T, Cushion M, Rappleye C, Willington M, Krysan D. The Celecoxib Derivative AR-12 has Broad Spectrum Antifungal Activity In vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis Antimicrob Agents Chemother 2016 Jan;60:7115-7127. Guevara-Suarez M, Sutton D, Cano J, Garcia D, Martin A, Wiederhold N, Guarro J, Gene. Identification and Antifungal Susceptibility of Penicillium-Like Fungi from Clinical Samples in the United States J Clin Microbiol 2016 Jan;54:2155-2161. Ziglioli V, Panciera DL, Sutton D, Wiederhold N, LeRoith T. Invasive Microsporum canis Causing Rhinitis and Stomatitis in a Cat J Small Anim Pract 2016 Jan;57:327-331. O?Donnell K, Sutton D, Wiederhold N, Robert V, Crous P, Geiser D. Veterinary Fusarioses within the United States J Clin Microbiol 2016 Jan;54:2813-2819. Fu J, Blaylock M, Wickes C, Welte W, Mehrtash A, Wiederhold N, Wickes B. Development of a Candida glabrata Dominant Nutritional Transformation Marker Utilizing the Aspergillus nidulans acetamidase gene (amdS) FEMS Yeast Res 2016 Jan;16. Siqueira JPZ, Sutton D, Gene J, Garcia D, Guevara M, Wiederhold N, Guarro J. Schizophyllum radiatum, an Emerging Fungus from Respiratory Tract Samples in USA J Clin Microbiol 2016 Jan;54:2491-2497. Sandoval-Denis M
  Gene J
  Sutton DA
  Cano-Lira JF
  de Hoog GS
  Decock CA
  Wiederhold NP
  Guarro J. Redefining Microascus, Scopulariopsis and Allied Genera Persoonia 2016 Jan;36:1-36. Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity Against Cryptococcus neoformans and Cryptococcus gattii Antimicrob Agents Chemother 2016 Jan;60:2528-2531. Sanchis M, Sutton DA, Wiederhold NP, Guarro J, Capilla J. Efficacy of Echinocandins against Murine Infections by Diutina (Candida) rugosa Diagn Microbiol Infect Dis 2016 Jan;81:61-65. Mackey PE, Cappe KG, Mani R, Rothenburg L, Sutton DA, Wiederhold NP, Lindner J, Ramachandran A, Wall CR, Snider T. Disseminated Conidiobolus incongruous in a Dog: A Case Report and Literature Review Med Mycol Case Rep 2015 Jun;8:24-28. Donnelly K, Waltzek TB, Wellehan JF, Sutton DA, Wiederhold NP, Stacy BA. Phaeohyphomycosis Resulting in Obstructive Tracheitis in Three Green Sea Turtles Chelonia mynas Stranded along the Florida Coast Dis Aquat Organ 2015 Apr;113(3):257-262. Farmer A
  Murray C
  Driscoll I
  Wickes B
  Wiederhold N
  Sutton D
  anders C
  Mende K
  Ennis B
  Feig J
  Ganesan A
  Rini E
  Vento T. Combat-Related Pythium aphanidermatum Invasive Wound Infection: A Case Report and Discussion of the Utility of Molecular Diagnostics J Clin Microbiol 2015 Jan;53:1968-1975. Sanchis M, Guarro J, Sutton DA, Fothergill AW, Wiederhold N, Capilla J. Voriconazole and Posaconazole Therapy for Experimental Candida lusitania Infection Diagn Microbiol Infect Dis 2015 Jan;84:48-51. Cho JC
  Sharma RS
  Sutton DA
  Wiederhold NP
  Sanders C
  Wickes BL
  Estrada SJ. Fungal Arthritis Secondary to Colletotrichum gloeosporioides J Med Microbiol Case Rep 2015 Jan;:1-5. Eghrari AO, Gibas C, Watkins T, Vahedi S, Lee R, Houle E, Suarez MJ, Eberhart C, Sutton D, Wiederhold NP, Sikder S, Zhang SX. First Human Case of Fungal Keratitis Caused by a Putatively Novel Species of Lophotrichus J Clin Microbio 2015 Jan;53(9):3063-3067. Saracli MA
  Fothergill AW
  Sutton DA
  Wiederhold NP. Detection of Triazole Resistance Among Candida Species by Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) Med Mycol 2015 Jan;53:736-742. Espinel-Ingroff A, Colombo A, Cordoba S, Dufresne P, Fuller J, Ghannoum M, Gonzalez G, Guarro J, Kidd S, Meis J, Melhem M, Pelaez T, Pfaller M, Szeszs M, Takahaschi J, Tortorano A, Wiederhold N, Turnidge J. An International Evaluation of MIC Distributions and ECV Definition for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method Antimicrob Agents Chemother 2015 Jan;60:1079-1984. 105. Yong LK, Wiederhold NP, Sutton DA, Sandoval-Denis M, Lindner JR, Fan H, Sanders C, Guarro J. Morphological and Molecular Characterization of Exophiala polymorphs, sp. nov., Isolated from Sporotrichoid Lymphocutaneous Lesions in a Patients with Myasthenia Gravis J Clin Microbiol 2015 Jan;53:2816-2822. Dionne B
  Neff L
  Lee SA
  Sutton DA
  Wiederhold NP
  Lindner J
  Fan H
  Jakeman B. Pulmonary Fungal Infection Caused by Neoscytalidium dimidiatum J Clin Microbiol 2015 Jan;53:2381-2384. Sandoval-Denis M, Sutton DA, Martin-Vicente A, Cano-Lira J, Wiederhold N, Guarro J, Gene J. Cladosporium Species Recovered from Clinical Samples in the United States J Clin Microbiol 2015 Jan;53:2990-3000. Sandoval-Denis M
  Gene J
  Sutton D
  Wiederhold N
  Guarro J. Acrophialophora, a Poorly Known Fungus with Clinical Significance J Clin Microbiol 2015 Jan;53:1549-1555. Lu LL, Weil AA, Wiederhold N, Sutton DA, Chesnut L, Lindner J, Fan H, Bhatraphol T, El-Khoury J, Kwon DS. A Probable Case of Cephalotheca foveolata Bloodstream Infection J Med Microbiol Case Repor 2015 Jan;2:1-5. Gebremarian T, Wiederhold NP, Fothergill AW, Garvey E, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS. VT-1161 Protects Immunosuppressed Mice from Rhizomes arrhizus var arrhizus Infection Antimicrob Agents Chemother 2015 Jan;59:7815-7817. Mor V
  Rella A
  Farnoud AM
  Singh A
  Munshi M
  Bryan A
  Naseem S
  Konopka JB
  Ojima I
  Bullesbach E
  Ashbaugh A
  Linke MJ
  Cushion M
  Collins M
  Ananthula H
  Desai PB
  Wiederhold NP
  Fothergill AW
  Kirkpatrick WR
  Patterson T
  Wong LH
  Sinha S
  Giaever G
  Nislow C
  Flaherty P
  Pan X
  Cesar GV
  de Melo Tavares P
  Frases S
  Miranda K
  Rodrigues ML
  Luberto C
  Nimrichter L
  Del Poeta M. Identification of New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids mBio 2015 Jan;6. Shubitz LF, Hien TT, Galgiani JN, Lewis ML Fothergill AW, Wiederhold NP, Barker BM, Lewis ERG, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP. Evaluation of VT-1161 for Treatment of Coccididoidomycosis in Murine Infection Models Antimicrob Agents Chemother 2015 Jan;59:7249-7254. Levy AC, Rehman S, Sutton DA, Burris KI, Hirschwerk DA, Chen S, Wiederhold NP, Fan H, Lindner J, Bhaskaran M, Ali N, Ali NM, Rilo HL, Molmenti EP. A Case of Phaeohyphomycosis Caused by Exophiala oligosperma in a Renal Transplant Patient Successfully Treated with Posaconazole Am J Infect Dis 2015 Jan;11:15-19. Sandoval-Denis M
  Sutton DA
  Cano-Lira JF
  Gene J
  Fothergill AW
  Wiederhold NP
  Guarro J. Phylogeny of the Clinically Relevant Species of the Emerging Fungus Trichoderma and their Antifungal Susceptibility J Clin Microbiol 2014 Apr;52(6):2112-2125. Walraven CJ, Bernardo ST, Wiederhold N, Lee SA. Paradoxical Antifungal Activity and Structural Observations in Biofilms Formed by Echinocandin-Resistant Candida albicans Clinical Isolates Med Mycol 2014 Apr;52(2):131-139. Langlois DK, Sutton DA, Swenson CL, Bailey CJ, Wiederhold NP, Nelson NC, Thompson EH, Wickes BL, French S, Fu J, Saavedra PV, Peterson SW. Clinical, Morphological, and Molecular Characterization of Penicillium canis, sp. nov., from a Dog with Osteomyelitis J Clin Microbiol 2014 Apr;52:2447-2453.

  Other

  Sutton DA, Stchigel A, Wiederhold NP, Guarro J, Cano J. Saksenaea trapezispora DA Sutton, Wiederhold, Guarro & Cano sp. nov. (Fungal Planet Descriptions Sheet - 487) Persoonia 2017 Jan;37:262-263. Guevara-Suarez M, Sutton D, Wiederhold N, Gene J. Neodactylaria obpyriformis (Fungal Planet Descriptions Sheet - 606) Persoonia 2017 Jan;38:344-345. Sandoval-Denis M, Gene J, Guarro J, Sutton DA, Wiederhold NP. Toxicladosporium hominis (Fungal Planet Description Sheet - 451) Persoonia 2016 Jan;36:420-421. Sandoval-Denis M, Gene J, Guarro J, Sutton DA, Wiederhold NP. Penidiellopsis radicularis (Fungal Planet Description Sheet - 460) Persoonia 2016 Jan;36:438-439. Guevara-Suarez M, Gene J, Cano-Lira J, da Cunha KC, Wiederhold NP. Pseudopithomyces diversisporus Guevara-Suarez, Da Cunha & Gene, sp. nov. (Fungal Planet Description Sheet - 486) Persoonia 2016 Jan;37. Sandoval-Denis M, Gene J, Guarro J, Sutton DA, Wiederhold NP. Toxicladosporium hominis (Fungal Planet Description Sheet - 460) Persoonia 2016 Jan;:420-421. Wiederhold NP, Sutton DA, Sandoval-Denis M, Guarro J. Polyschema sclerotigenum (Fungal Planet Description Sheets - 358) Persoonia 2015 Jan;53:238-239.

  Review Article

  Gibas CF, Wiederhold NP. The Black Yeasts: An Update on Species Identification and Diagnosis Curr Fungal Infect Repor (In Press) 2018 Jan;. Seyedmojtaba S, Bosco S, de Hoog GS, Ebel F, Elad D, Gomes R, Jacobsen ID, Martel A, Mignon B, Pasman S, Piekova E, Rodrigues AM, Singh K, Vicente V, Wibbelt G, Wiederhold N, Guillot J. Fungal Infections in Animals: A Patchwork of Different Situations Med Mycol 2018 Jan;56:S165-S187. Wiederhold NP, Gibas CFC. From the Clinical Microbiology Laboratory: New Speces and Changes in Fungal Taxonomy and Nomenclature J Fungi 2018 Jan;. Wiederhold NP. The Antifungal Arsenal: Alternative Drugs and Future Targets Int J Antimicrob Agents 2018 Jan;51:333-339. Wickes BL, Wiederhold NP. Molecular Diagnostics in Medical Mycology Nature Commun 2018 Jan;9. Perlin DS, Wiederhold NP. Culture-Independent Molecular Methods for Antifungal Resistance Mechanisms and Fungal Identification J Infect Dis 2017 Jan;216:S458-S465. Wiederhold NP. Antifungal Resistance: Current Trends and Future Strategies Infect Drug Resist 2017 Jan;10:249-259. Schwartz IS, Wiederhold NP. Update on Therapeutic Drug Monitoring of Antifungals for the Prophylaxis and Treatment of Invasive Fungal Infections Curr Fungal Infect Rep (In Press) 2017 Jan;. Wiederhold NP. Pharmacokinetics and Safety of Posaconazole Delayed Release Tablets for Invasive Fungal Infections Clin Pharmacol 2016 Jan;8:1-8. Wiederhold NP. Echinocandin Resistance in Candida Species: A Review of Recent Developments Curr Infect Dis Rep 2016 Jan;18. Albataineh MT, Sutton DA, Fothergill AW, Wiederhold NP. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance Infect Dis Clin N Am 2016 Jan;30:13-35. Wiederhold NP
  Patterson TF. Emergence of Azole Resistance in Aspergillus Semin Resp Crit Care Med 2015 Jan;36:673-680. Wiederhold NP, Patterson TF. What?s New in Antifungals: An Update on the In Vitro Activity and In Vivo Efficacy of New and Investigational Antifungal Agents Curr Opin Infect Dis 2015 Jan;28:539-545.